Article
Transcriptomic classes of BCR-ABL1 lymphoblastic leukemia
19 Jun 2023
Abstract excerpt
Abstract In BCR-ABL1 lymphoblastic leukemia, treatment heterogeneity to tyrosine kinase inhibitors (TKIs), especially in the absence of kinase domain mutations in BCR-ABL1, is poorly understood. Through deep molecular profiling, we uncovered three transcriptomic subtypes of BCR-ABL1 lymphoblastic leukemia, each representing a maturation arrest at a stage of B-cell progenitor differentiation. An earlier arrest was...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
